NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04153149,HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy,https://clinicaltrials.gov/study/NCT04153149,,ACTIVE_NOT_RECRUITING,This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.,NO,Transthyretin Amyloidosis (ATTR) With Cardiomyopathy,DRUG: Vutrisiran|DRUG: Sterile Normal Saline (0.9% NaCl),"Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population, All-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) will be compared between treatment groups using an Andersen-Gill model., Up to Month 36|Composite Endpoint of All-Cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) in the Vutrisiran Monotherapy Subgroup, All-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) will be compared between treatment groups using an Andersen-Gill model. The vutrisiran monotherapy subgroup is defined as the group of participants not on tafamidis at the study baseline., Up to Month 36","Change from Baseline in 6-Minute Walk Test (6-MWT) in the Overall Population and Vutrisiran Monotherapy Subgroup, Baseline to Month 30|Change from Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) in the Overall Population and Vutrisiran Monotherapy Subgroup, The KCCQ is a 23-item self-administered questionnaire quantifying 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary \[OS\]). Scores are transformed to a range of 0-100, in which higher scores reflect better health status., Baseline to Month 30|All-cause Mortality in the Overall Population and Vutrisiran Monotherapy Subgroup, Up to 42 months|Change from Baseline in New York Heart Association (NYHA) Class in the Overall Population and Vutrisiran Monotherapy Subgroup, Baseline to Month 30",,Alnylam Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,655,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",ALN-TTRSC02-003|2019-003153-28|2023-508366-15,2019-11-26,2024-05-08,2026-12-01,2019-11-06,,2025-02-17,"Clinical Trial Site, Stanford, California, 94305, United States|Clinical Trial Site, Washington, District of Columbia, 20010, United States|Clinical Trial Site, Gainesville, Georgia, 30501, United States|Clinical Trial Site, Evanston, Illinois, 60201, United States|Clinical Trial Site, Boston, Massachusetts, 02115, United States|Clinical Trial Site, Boston, Massachusetts, 02118, United States|Clinical Trial Site, Rochester, Minnesota, 55902, United States|Clinical Trial Site, Manhasset, New York, 11030, United States|Clinical Trial Site, New York, New York, 10032, United States|Clinical Trial Site, Durham, North Carolina, 27710, United States|Clinical Trial Site, Cleveland, Ohio, 44195, United States|Clinical Trial Site, Philadelphia, Pennsylvania, 19104, United States|Clinical Trial Site, Houston, Texas, 77030, United States|Clinical Trial Site, Buenos Aires, Argentina|Clinical Trial Site, Adelaide, Australia|Clinical Trial Site, Melbourne, Australia|Clinical Trial Site, Sydney, Australia|Clinical Trial Site, Westmead, Australia|Clinical Trial Site, Woolloongabba, Australia|Clinical Trial Site, Vienna, Austria|Clinical Trial Site, Anderlecht, Belgium|Clinical Trial Site, Dendermonde, Belgium|Clinical Trial Site, Ghent, Belgium|Clinical Trial Site, Leuven, Belgium|Clinical Trial Site, Quebec City, Canada|Clinical Trial Site, Toronto, Canada|Clinical Trial Site, Zagreb, Croatia|Clinical Trial Site, Olomouc, Czechia|Clinical Trial Site, Prague, Czechia|Clinical Trial Site, Aarhus, Denmark|Clinical Trial Site, Odense, Denmark|Clinical Trial Site, Créteil, France|Clinical Trial Site, Marseille, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Toulouse, France|Clinical Trial Site, Essen, Germany|Clinical Trial Site, Göttingen, Germany|Clinical Trial Site, Heidelberg, Germany|Clinical Trial Site, Leipzig, Germany|Clinical Trial Site, Münster, Germany|Clinical Trial Site, Würzburg, Germany|Clinical Trial Site, Budapest, Hungary|Clinical Trial Site, Dublin, Ireland|Clinical Trial Site, Haifa, Israel|Clinical Trial Site, Aichi, Japan|Clinical Trial Site, Fukuoka, Japan|Clinical Trial Site, Kagawa, Japan|Clinical Trial Site, Kashihara, Japan|Clinical Trial Site, Kumamoto, Japan|Clinical Trial Site, Matsumoto, Japan|Clinical Trial Site, Nankoku, Japan|Clinical Trial Site, Osaka, Japan|Clinical Trial Site, Tokyo, Japan|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Riga, Latvia|Clinical Trial Site, Kaunas, Lithuania|Clinical Trial Site, Groningen, Netherlands|Clinical Trial Site, Utrecht, Netherlands|Clinical Trial Site, Oslo, Norway|Clinical Trial Site, Lima, Peru|Clinical Trial Site, San Miguel, Peru|Clinical Trial Site, Gdańsk, Poland|Clinical Trial Site, Wrocław, Poland|Clinical Trial Site, Guimarães, Portugal|Clinical Trial Site, Lisboa, Portugal|Clinical Trial Site, Porto, Portugal|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Bilbao, Spain|Clinical Trial Site, Huelva, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Málaga, Spain|Clinical Trial Site, Gothenburg, Sweden|Clinical Trial Site, Umeå, Sweden|Clinical Trial Site, Birmingham, United Kingdom|Clinical Trial Site, Cardiff, United Kingdom|Clinical Trial Site, Glasgow, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, Manchester, United Kingdom|Clinical Trial Site, Middlesbrough, United Kingdom",
